KA 3001
Alternative Names: KA-3001Latest Information Update: 15 Jul 2024
At a glance
- Originator KYinno Biotechnology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD28 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer